TLR2 recognizes a wide range of bacterial components and a combination of TLR2/TLR9 agonists has demonstrated a significant protective effect against both Antibody (Ab) lethal and sublethal infections, and also promotes killing or phagocytosis of Ab by lung epithelial cells and macrophages cells (Scharf et al., 2010). The gene discussed is TLR2; the disease is infection.